Therefore, our results suggest that FPR2 is a key target for understanding sex differences in NAFLD/NASH and has therapeutic potential for the prevention and treatment of NAFLD. This evidence concerns the gene FPR2 and metabolic dysfunction-associated steatohepatitis.